JAK-IN-5 | JAK Inhibitor | AmBeed-信号通路专用抑制剂

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	1周咨询	- +

产品名称	JAK1 ↓ ↑	JAK2 ↓ ↑	JAK3 ↓ ↑	Tyk2 ↓ ↑	其他靶点	纯度
Decernotinib	+++ JAK1, Ki: 11 nM JAK1, IC50: 11 nM	+++ JAK2, Ki: 13 nM	++++ JAK3, Ki: 2.5 nM	+++ TYK2, Ki: 13 nM		99%+
ZM39923 HCl	+ JAK1, pIC50: 4.4		+ JAK3, pIC50: 7.1		EGFR	97%
Cerdulatinib	+++ JAK1, IC50: 12 nM	+++ JAK2, IC50: 6 nM	+++ JAK3, IC50: 8 nM	++++ TYK2, IC50: 0.5 nM		99%+
Momelotinib	+++ JAK1, IC50: 11 nM	++ JAK2, IC50: 18 nM	+ JAK3, IC50: 155 nM			99%+
XL019	+ JAK1, IC50: 134.3 nM	++++ JAK2, IC50: 2.2 nM	+ JAK3, IC50: 214.2 nM		FLT3	99%+
Ruxolitinib	+++ JAK1, IC50: 3.3 nM	++++ JAK2, IC50: 2.8 nM				98%
Tofacitinib	+ JAK1, IC50: 112 nM	++ JAK2, IC50: 20 nM	++++ JAK3, IC50: 1 nM			98%
Ruxolitinib (S enantiomer)	+++ JAK1, IC50: 3.3 nM	++++ JAK2, IC50: 2.8 nM		++ TYK2, IC50: 19 nM		98%
Filgotinib	+++ JAK1, IC50: 10 nM	++ JAK2, IC50: 28 nM	+ JAK3, IC50: 810 nM	+ TYK2, IC50: 116 nM		99%
Baricitinib	+++ JAK1, IC50: 5.9 nM	+++ JAK2, IC50: 5.7 nM		++ TYK2, IC50: 53 nM		99%
Gandotinib	++ JAK1, IC50: 19.8 nM	++++ JAK2 (V617F), Ki: 0.245 nM JAK2, IC50: 0.288 nM	++ JAK3, IC50: 48.0 nM	++ TYK2, IC50: 44 nM	FLT3	99%+
Oclacitinib maleate	+++ JAK1, IC50: 10nM	++ JAK2, IC50: 18nM	+ JAK3, IC50: 99nM	+ TYK2, IC50: 84nM		98+%
NVP-BSK805 2HCl	++ JAK1, IC50: 31.63 nM	++++ JAK2, IC50: ~0.5 nM	++ JAK3, IC50: 18.68 nM	+++ TYK2, IC50: 10.76 nM		95%
Peficitinib		✔				98%
Go6976		✔			FLT3	99%+
AZD-1480		++++ JAK2, IC50: 0.26 nM				99%+
Fedratinib		+++ JAK2, IC50: 3 nM JAK2 (V617F), IC50: 3 nM			RET,FLT3	99%+
WP1066		+ JAK2, IC50: 2.3 μM				98%
Curcumol		✔				98%
AZ960		++++ JAK2, IC50: <3 nM JAK2, Ki: 0.45 nM				97%
GLPG0634 analog		✔				99%+
CEP-33779		++++ JAK2, IC50: 1.8 nM				99%+
FLLL32		+ JAK2, IC50: <5 μM				99%+
WHI-P154			+ JAK3, IC50: 1.8 μM		Src,EGFR,VEGFR	98%
BMS-911543		++++ JAK2, IC50: 1.1 nM	+ JAK3, IC50: 75 nM	++ TYK2, IC50: 66 nM		95%
TG101209		+++ JAK2, IC50: 6 nM	+ JAK3, IC50: 169 nM		RET,FLT3	99%+
AT9283		++++ JAK2, IC50: 1.2 nM	++++ JAK3, IC50: 1.1 nM			99%+
Pacritinib		++ JAK2, IC50: 23 nM JAK2 (V617F), IC50: 19 nM	+ JAK3, IC50: 520 nM	++ TYK2, IC50: 50 nM	FLT3	97%
Tofacitinib citrate		++ JAK2, IC50: 20 nM	++++ JAK3, IC50: 1 nM			99%
FM-381			++++ JAK3, IC50: 127 pM			98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT00494585	Leukemia Myel... 展开 >>ofibrosis 收起 <<	Phase 2	Completed	-	United States, Texas ... 展开 >> The University of Texas M.D. Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT00494585	-		Completed	-	-
NCT03425006	Non Small Cell Lung Cancer	Phase 2	Recruiting	June 2021	United States, Pennsylvania ... 展开 >> University of Pennsylvania Recruiting Philadelphia, Pennsylvania, United States, 19104 Contact: Melissa Volpe 215-220-9703 Melissa.volpe@uphs.upenn.edu 收起 <<
NCT02426086	Primary Myelofibrosis	Phase 2	Active, not recruiting	April 26, 2019	-
NCT03564470	Leukemia Leuk... 展开 >>emia, Acute Leukemia, Lymphoblastic Leukemia, B-cell 收起 <<	Phase 2 Phase 3	Recruiting	August 30, 2020	China, Guangdong ... 展开 >> Department of Hematology, Nanfang Hospital Recruiting Guangzhou, Guangdong, China, 510515 Contact: Hongsheng Zhou, PhD, MD 86-20-62787349 zhs1@i.smu.edu.cn 收起 <<
NCT02493530	Myelofibrosis ... 展开 >> Polycythemia Vera 收起 <<	Phase 1	Recruiting	December 2019	United States, Arizona ... 展开 >> Mayo Clinic - Arizona Recruiting Phoenix, Arizona, United States, 85054 Contact: Clinical Trials Office 855-776-0015 Principal Investigator: Ruben Mesa, MD United States, Colorado University of Colorado Cancer Center Recruiting Aurora, Colorado, United States, 80045 Contact: Clinical Trials Office 720-848-0018 Principal Investigator: Daniel A Pollyea, MD, MS United States, Tennessee Vanderbilt-Ingram Cancer Center Recruiting Nashville, Tennessee, United States, 37232 Contact: Clinical Trials Office 800-811-8480 Principal Investigator: Michael R Savona, MD United States, Wisconsin Medical College of Wisconsin Recruiting Milwaukee, Wisconsin, United States, 53226 Contact: Clinical Trials Office 414-805-1118 Principal Investigator: Laura C. Michaelis, MD 收起 <<
NCT00522574	Myeloproliferative Disorders ... 展开 >> Myelofibrosis Polycythemia Vera Thrombocythemia, Essential 收起 <<	Phase 1	Terminated(Due to emerging saf... 展开 >>ety data) 收起 <<	-	United States, California ... 展开 >> UCSF - Division of Hematology/Oncology San Francisco, California, United States, 94143 United States, Florida H. Lee Moffitt Cancer Center & Research Institute Tampa, Florida, United States, 33612 United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, New York Mt. Sinai School of Medicine New York, New York, United States, 10029 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT01693601	Myelofibrosis	Phase 1 Phase 2	Active, not recruiting	February 2019	United States, New York ... 展开 >> Icahn School of Medicine at Mount Sinai New York, New York, United States, 10029 收起 <<
NCT01976364	Arthritis, Psoriatic	Phase 3	Active, not recruiting	July 11, 2019	-
NCT01185353	Arthritis, Rheumatoid	Phase 2	Completed	-	-
NCT01219543	Solid Tumour ... 展开 >>Advanced Solid Malignancies Child-Pugh A to B7 Advanced Hepatocellular Carcinoma EGFR and/or ROS Mutant NSCLC Lung Metastasis Carcinoma Gastric Cancer 收起 <<	Phase 1	Terminated(Compound developmen... 展开 >>t discontinued) 收起 <<	-	Korea, Republic of ... 展开 >> Research Site Seoul, Korea, Republic of 收起 <<
NCT01905813	B-cell Malignancies	Phase 1	Active, not recruiting	December 2019	United States, Alabama ... 展开 >> Birmingham, Alabama, United States United States, Florida Jacksonville, Florida, United States United States, Michigan Ann Arbor, Michigan, United States United States, Minnesota Rochester, Minnesota, United States United States, New York New York, New York, United States Rochester, New York, United States 收起 <<
NCT00719836	Acute Myelogenous Leukemia ... 展开 >> Chronic Myelogenous Leukemia Chronic Myelomonocytic Leukemia Myelodysplastic Syndromes Myelofibrosis 收起 <<	Phase 1 Phase 2	Completed	-	United States, Illinois ... 展开 >> The University of Chicago Hospitals Chicago, Illinois, United States, 60637 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 United States, Washington Fred Hutchinson Cancer Center Seattle, Washington, United States, 98109 收起 <<
NCT03613428	Acute T Cell Leukemia	Phase 1 Phase 2	Not yet recruiting	March 30, 2021	-
NCT00934544	Myelofibrosis	Phase 3	Completed	-	-
NCT03765554	Healthy Participants	Phase 1	Not yet recruiting	March 12, 2019	-
NCT01776723	Myelomonocytic Leukemia	Phase 1 Phase 2	Active, not recruiting	April 2020	United States, Florida ... 展开 >> H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 United States, Maryland Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland, United States, 21287 United States, Massachusetts Brigham and Women's Hospital Boston, Massachusetts, United States, 02115 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, New York Weill Medical College of Cornell New York, New York, United States, 10021 United States, Ohio Cleveland Clinic Cleveland, Ohio, United States, 44106 收起 <<
NCT00928707	Polycythemia Vera	Phase 2	Completed	-	Italy ... 展开 >> Azienda Ospedaliero-Universitaria Policlinico Consorziale di Bari Bari, BA, Italy, 70124 Azienda Ospedaliera Santa Croce e Carle di Cuneo Cuneo, CN, Italy, 12100 Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione Garibaldi di Catania Catania, CT, Italy, 95126 Fondazione I. R. C. C. S. - Casa sollievo della sofferenza di San Giovanni Rotondo San Giovanni Rotondo, FG, Italy, 71013 Azienda Ospedaliero-Universitaria Careggi di Firenze Florence, FI, Italy, 50134 Azienda Ospedaliera San Gerardo di Monza Monza, MB, Italy, 20052 Azienda Ospedaliera Universitaria Policlinico "Gaetano Martino" di Messina Messina, ME, Italy, 98125 Azienda Ospedaliera Ospedali Riuniti "Villa Sofia - Cervello" di Palermo Palermo, PA, Italy, 90146 Azienda Unità Sanitaria Locale di Pescara, Presidio Ospedaliero "Spirito Santo" Pescara, PE, Italy, 65124 Azienda Ospedaliera Santa Maria della Misericordia di Perugia Perugia, PG, Italy, 06156 Azienda Ospedaliera Universitaria Pisana Pisa, PI, Italy, 56126 Azienda Ospedaliera Ospedale San Carlo di Potenza Potenza, PT, Italy, 85100 Fondazione I.R.C.C.S.-Policlinico San Matteo, Pavia Pavia, PV, Italy, 27100 Azienda Ospedaliera "Bianchi-Melacrino-Morelli" Reggio di Calabria, RC, Italy, 891225 Azienda Ospedaliera Universitaria S. Luigi Gonzaga di Orbassano Orbassano, TO, Italy, 10043 Azienda Ospedaliero-Universitaria San Giovanni Battista("Le Molinette") di Torino Torino, TO, Italy, 10126 Ospedale Mauriziano Umberto I Torino, TO, Italy, 10128 Ospedale San Bortolo di Vicenza Vicenza, VI, Italy, 36100 Azienda Ospedaliera Ospedali Riuniti di Bergamo Bergamo, Italy, 24100 Azienda Ospedaliera Universitaria Università degli Studi di Napoli Federico II Napoli, Italy, 80131 Università "Campus Bio-Medico", Rome Rome, Italy, 00128 Policlinico Universitario Agostino Gemelli di Roma Rome, Italy, 00168 收起 <<
NCT00147498	Rheumatoid Arthritis	Phase 2	Completed	-	-
NCT00934544	-		Completed	-	-
NCT01185353	-		Completed	-	-
NCT01309737	Psoriasis	Phase 3	Completed	-	-
NCT02119663	Pancreatic Cancer	Phase 3	Terminated(The safety committe... 展开 >>e found no safety issues but recommended halting the study based on a lack of efficacy in a similar trial. The sponsor terminated the trial.) 收起 <<	-	-
NCT01790295	Primary Myelofibrosis ... 展开 >> Post Polycythemia Vera Myelofibrosis Post Essential Thrombocythemia Myelofibrosis 收起 <<	Phase 2	Active, not recruiting	February 2021	United States, Georgia ... 展开 >> Emory Hospital Atlanta, Georgia, United States, 30322 United States, Illinois Northwestern University, Robert h. Lurie Comprehensive Cancer Center Chicago, Illinois, United States, 60611 United States, Kansas University of Kansas Cancer Center Westwood, Kansas, United States, 66205 United States, New York Icahn School of Medicine at Mount Sinai New York, New York, United States, 10029 United States, North Carolina Wake Forest Baptist Medical Center Winston-Salem, North Carolina, United States, 27103 United States, Ohio Ohio State University Columbus, Ohio, United States, 43210 Canada Princess Margaret Cancer Centre, University of Toronto Toronto, Canada, M5G 2M9 United Kingdom University of Oxford Oxford, United Kingdom, OX3 9DS 收起 <<
NCT02018861	B-Cell Malignancies	Phase 1 Phase 2	Active, not recruiting	January 2019	United States, Alabama ... 展开 >> Birmingham, Alabama, United States United States, Arizona Tucson, Arizona, United States United States, Florida Port Saint Lucie, Florida, United States United States, Indiana Indianapolis, Indiana, United States United States, Kansas Kansas City, Kansas, United States United States, Michigan Ann Arbor, Michigan, United States Detroit, Michigan, United States United States, New Jersey Hackensack, New Jersey, United States United States, New York New York, New York, United States United States, Ohio Cleveland, Ohio, United States United States, South Carolina Greenville, South Carolina, United States United States, Tennessee Knoxville, Tennessee, United States United States, Texas Dallas, Texas, United States Houston, Texas, United States 收起 <<
NCT01981681	Healthy	Phase 1	Completed	-	Belgium ... 展开 >> Pfizer Investigational Site Brussels, Belgium, B-1070 收起 <<
NCT00147498	-		Completed	-	-
NCT02119663	-		Terminated(The safety committe... 展开 >>e found no safety issues but recommended halting the study based on a lack of efficacy in a similar trial. The sponsor terminated the trial.) 收起 <<	-	-
NCT01309737	-		Completed	-	-
NCT00866762	Polycythemia Vera ... 展开 >> Essential Thrombocythemia 收起 <<	Phase 2	Unknown	December 2012	Denmark ... 展开 >> Copenhagen University Hospital Rigshospitalet Copenhagen, Denmark, DK-2100 Esberg Hospital Esbjerg, Denmark, DK-6700 Herlev Hospital Herlev, Denmark, DK-2730 Odense University Hospital Odense, Denmark, DK-5000 Roskilde Hospital Roskilde, Denmark, DK-4000 Regional Hospital Viborg Viborg, Denmark, DK-8800 Netherlands VU University Medical Centre Amsterdam, Netherlands, 1081 HV Sweden University Hospital Orebro Orebro, Sweden, S-70185 Stockholm South General Hospital (Sodersjukhuset) Stockholm, Sweden, S-11883 Karolinska University Hospital Huddinge Stockholm, Sweden, S-14186 Sahlgrenska University Hospital & Uddevalla Hospital Uddevalla, Sweden, S-45180 Uppsala University Hospital Uppsala, Sweden, S-75185 United Kingdom Centre for Cancer Research and Cell Biology, Queen's University Belfast Belfast, Northern Ireland, United Kingdom, BT9 7AB Cardiff University Cardiff, United Kingdom, CF14 4XN Russell's Hall Hospital Dudley, United Kingdom, DY1 2HQ St Thomas' Hospital London, United Kingdom, SE1 7EH 收起 <<
NCT01039688	Arthritis, Rheumatoid	Phase 3	Completed	-	-
NCT00910728	-		Completed	-	-
NCT01815424	Psoriasis	Phase 3	Completed	-	China, Beijing ... 展开 >> Dept. Of dermatology &STD, Beijing Friendship Hospital, Capital Medical University Xicheng District, Beijing, China, 100050 China, Guangdong Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University Guangzhou, Guangdong, China, 510120 China, Hubei Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan, Hubei, China, 430022 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan, Hubei, China, 430030 China, Jiangsu Hospital of Skin Diseases, Chinese Academy of Medical Sciences Nanjing, Jiangsu, China, 210042 China, Liaoning Department of Dermatology, The Second Affiliated Hospital of Dalian Medical University Dalian, Liaoning, China, 116027 China, Shanghai Huashan Hospital, Fudan University/Dermatology Department Shanghai, Shanghai, China, 200040 Shanghai Changhai Hospital, Dermatology Department Shanghai, Shanghai, China, 200433 China, Shanxi Dermatology Department, The First Affiliated Hospital, The Fourth Military Medical University Xi'an, Shanxi, China, 710032 China, Sichuan Sichuan Provincial People's Hospital Chengdu, Sichuan, China, 610031 West China Hospital of Sichuan University Chengdu, Sichuan, China, 610041 China, Zhejiang The First Affiliated Hospital of College of Medicine, Zhejiang University/Dermatology and STD Dept Hangzhou, Zhejiang, China, 310003 The Second Affiliated Hospital of College of Medicine, Zhejiang University Hangzhou, Zhejiang, China, 310009 China Peking University First Hospital / The Department of Dermatology Beijing, China, 100034 Peking University People's Hospital/Dermatology Department Beijing, China, 100044 Beijing Hospital of the Ministry of Health/Department of Dermatology Beijing, China, 100730 Peking Union Medical College Hospital/Department of Dermatology Beijing, China, 100730 Tianjin Medical University General Hospital, Dermatological Department Tianjin, China, 300052 Korea, Republic of Seoul National University Hospital Seoul, Korea, Republic of, 110-744 Department of Dermatology,Severance Hospital, Yonsei University Health System Seoul, Korea, Republic of, 120-452 Samsung Medical Center Seoul, Korea, Republic of, 135-710 Taiwan National Cheng-Kung University Hospital Tainan, Taiwan, 704 National Taiwan University Hospital Taipei, Taiwan, 100 Chang Gung Medical Foundation-Linkou Branch Taoyuan, Taiwan, 333 收起 <<
NCT01458574	Ulcerative Colitis	Phase 3	Completed	-	-
NCT01251965	Leukemia	Phase 1 Phase 2	Completed	-	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT02281552	-		Completed	-	-
NCT01732445	-		Completed	-	-
NCT01458574	-		Completed	-	-
NCT02281552	Rheumatoid Arthritis	Phase 3	Completed	-	Japan ... 展开 >> Japanese Red Cross Nagoya Daiichi Hospital Nagoya, Aichi, Japan, 453-8511 National Hospital Organization Nagoya Medical Center Nagoya, Aichi, Japan, 460-0001 National Hospital Organization Toyohashi Medical Center Toyohashi, Aichi, Japan, 440-8510 Yamada Rheumatology Clinic Matsuyama, Ehime, Japan, 790-0905 St. Mary's Hospital Kurume, Fukuoka, Japan, 830-8543 Gunma Rheumatism Clinic Takasaki-shi, Gunma, Japan, 370-0004 Inoue Hospital Tohrimachi, Takasaki, Gunma, Japan, 370-0053 Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital Hiroshima-city, Hiroshima, Japan, 730-8619 National Hospital Organization Asahikawa Medical Center Asahikawa, Hokkaido, Japan, 070-8644 Katayama Orthopaedic Rheumatology Clinic Asahikawa, Hokkaido, Japan, 078-8243 Yoshida orthopaedics and rheumatologyclinic Morioka, Iwate, Japan, 020-0015 Komagamine Rheumatoid Orthopaedic Clinic Morioka, Iwate, Japan, 020-0034 National Hospital Organization Sagamihara National Hospital Sagamihara, Kanagawa, Japan, 252-0392 National Hospital Organization Yokohama Medical Center Yokohama, Kanagawa, Japan, 245-8575 Osaki Citizen Hospital Oosaki, Miyagi, Japan, 989-6183 Tohoku University Hospital/ Department of Hematology and Rheumatology Sendai, Miyagi, Japan, 9808574 Nagano Red Cross Hospital Nagano-shi, Nagano, Japan, 380-8582 Sasebo Chuo Hospital Sasebo, Nagasaki, Japan, 857-1195 National Hospital Organization Ureshino Medical Center Ureshino-shi, Saga, Japan, 843-0393 Soshigayaokura clinic Setagaya-ku, Tokyo, Japan, 157-0073 Showa University Hospital Shinagawa-ku, Tokyo, Japan, 142-8666 Honjo Rheumatism Clinic Takaoka-shi, Toyama, Japan, 933-0874 Miyasato Clinic Shunan, Yamaguchi, Japan, 745-0824 National Hospital Organization Chiba-East Hospital Chiba, Japan, 260-8712 Sugimoto rheumatology and internal medicine clinic Fukui, Japan, 910-0068 National Hospital Organization Kyushu Medical Center Fukuoka, Japan, 810-8563 SHONO Rheumatism Clinic Fukuoka, Japan, 814-0002 Sagawa Akira Rheumatology Clinic Hokkaido, Japan, 060-0001 Matsubara Mayflower Hospital Hyogo, Japan, 673-1462 Yokohama Minami Kyosai Hospital Kanagawa, Japan, 236-0037 Kumamoto Orthopaedic Hospital Kumamoto, Japan, 862-0976 Japanese Red Cross Kyoto Daiichi Hospital Kyoto, Japan, 605-0981 Oribe Clinic of Rheumatology and Internal Medicine Oita, Japan, 870-0823 Otsuka Clinic of Rheumatism and Medicine Oita, Japan, 870-1155 Rabbit Clinic Saitama, Japan, 336-0911 Hirose Clinic Saitama, Japan, 359-1111 收起 <<
NCT01732445	Anemia Primar... 展开 >>y Myelofibrosis Secondary Myelofibrosis 收起 <<	Phase 2	Completed	-	United States, Arizona ... 展开 >> Mayo Clinic in Arizona Scottsdale, Arizona, United States, 85259 United States, New York Tisch Cancer Center New York, New York, United States, 10029 收起 <<
NCT00910728	Primary Myelofibrosis (PMF) ... 展开 >> Post-Polycythaemia Vera Essential Thrombocythaemia Myelofibrosis 收起 <<	Phase 1	Completed	-	United States, New York ... 展开 >> Research Site New York, New York, United States United States, Texas Research Site Houston, Texas, United States France Research Site Villejuif Cedex, France 收起 <<
NCT00509899	Myelofibrosis ... 展开 >> Polycythemia Vera Thrombocytosis 收起 <<	Phase 1 Phase 2	Completed	-	United States, Minnesota ... 展开 >> Rochester, Minnesota, United States United States, Texas Houston, Texas, United States 收起 <<
NCT00595829	Polycythemia Vera	Phase 1	Terminated	-	United States, California ... 展开 >> UCLA School of Medicine, Center for Health Sciences Los Angeles, California, United States, 90095 UCSF - Division of Hematology/Oncology San Francisco, California, United States, 94143 United States, Florida H. Lee Moffitt Cancer Center & Research Institute Tampa, Florida, United States, 33612 United States, Michigan University of Michigan Health System Ann Arbor, Michigan, United States, 48109 United States, New York Weill Cornell Medical College New York, New York, United States, 10065 收起 <<
NCT01787552	Primary Myelofibrosis ... 展开 >> Thrombocythemia, Essential Thrombocytosis Myeloproliferative Disorders Bone Marrow Diseases Hematologic Diseases Blood Coagulation Disorders Blood Platelet Disorders Hemorrhagic Disorders 收起 <<	Phase 1 Phase 2	Completed	-	Australia, New South Wales ... 展开 >> Novartis Investigative Site Camperdown, New South Wales, Australia, NSW Australia, Queensland Novartis Investigative Site Woolloongabba, Queensland, Australia, 4102 Belgium Novartis Investigative Site Leuven, Belgium, 3000 Canada, Ontario Novartis Investigative Site Toronto, Ontario, Canada, M5G 2M9 Canada, Quebec Novartis Investigative Site Montreal, Quebec, Canada, H3T 1E2 Denmark Novartis Investigative Site Roskilde, Denmark, 4000 France Novartis Investigative Site Marseille, France, 13273 Germany Novartis Investigative Site Aachen, Germany, 52074 Novartis Investigative Site Magdeburg, Germany, 39120 Ireland Novartis Investigative Site Galway, Ireland Italy Novartis Investigative Site Firenze, FI, Italy, 50134 Novartis Investigative Site Reggio Calabria, RC, Italy, 89124 Netherlands Novartis Investigative Site Amsterdam, Netherlands, 1081 HV Novartis Investigative Site Rotterdam, Netherlands, 3015 GD Spain Novartis Investigative Site Barcelona, Catalunya, Spain, 08036 Novartis Investigative Site Madrid, Spain, 28034 United Kingdom Novartis Investigative Site Glasgow, Scotland, United Kingdom, G12 0YN Novartis Investigative Site London, United Kingdom, SE1 9RT 收起 <<
NCT03760003	Ulcerative Colitis	Phase 2	Not yet recruiting	September 30, 2020	-
NCT01039688	-		Completed	-	-
NCT00668421	Myelofibrosis ... 展开 >> Essential Thrombocythemia Polycythemia Vera 收起 <<	Phase 1 Phase 2	Unknown	January 2015	United States, California ... 展开 >> Palo Alto Medical Facilities Palo Alto, California, United States, 94301 United States, District of Columbia Georgetown University Medicine Center Washington, District of Columbia, United States, 20007 United States, Maryland University of Maryland Marlene and Stewart Greenebaum Cancer Center Baltimore, Maryland, United States, 21201 United States, New York Weill Cornell Ithaca, New York, United States, 14851 Icahn School of Medicine at Mount Sinai New York, New York, United States, 10029 United States, Pennsylvania University of Pennsylvania Philadelphia, Pennsylvania, United States, 19107 United States, Utah University of Utah Salt Lake City, Utah, United States, 84102 收起 <<
NCT02117479	Pancreatic Cancer	Phase 3	Terminated(The study was termi... 展开 >>nated early based on the results of the planned interim analysis.) 收起 <<	-	-
NCT03395340	Graft Versus Host Disease ... 展开 >> JNS Kinase Topical Administration 收起 <<	Phase 2	Recruiting	October 1, 2019	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) 800-411-1222 ext TTY8664111010 prpl@cc.nih.gov 收起 <<
NCT00509899	-		Completed	-	-
NCT02201524	Plaque Psoriasis	Phase 2	Terminated(Study terminated 26... 展开 >> June 2015 due to changes in the drug development portfolio. This study was not terminated for reasons of safety and/or efficacy) 收起 <<	-	-
NCT03627052	Moderate to Severe Ulcerative ... 展开 >>Colitis 收起 <<	Phase 2	Recruiting	April 2021	United States, Florida ... 展开 >> Advanced Pharma Recruiting Miami, Florida, United States, 33147 Principal Investigator: Dr. Kimberly Cruz 收起 <<
NCT02201524	-		Terminated(Study terminated 26... 展开 >> June 2015 due to changes in the drug development portfolio. This study was not terminated for reasons of safety and/or efficacy) 收起 <<	-	-
NCT00639002	Multiple Myeloma	Phase 2	Completed	-	United States, California ... 展开 >> Highland, California, United States, 92346 United States, Florida Boynton Beach, Florida, United States, 33435 United States, New York New York, New York, United States, 10011 收起 <<
NCT01186744	Psoriasis	Phase 3	Completed	-	-
NCT02117479	-		Terminated(The study was termi... 展开 >>nated early based on the results of the planned interim analysis.) 收起 <<	-	-
NCT02251821	Primary Myelofibrosis ... 展开 >> Secondary Myelofibrosis 收起 <<	Phase 2	Recruiting	-	United States, Washington ... 展开 >> Fred Hutch/University of Washington Cancer Consortium Recruiting Seattle, Washington, United States, 98109 Contact: Rachel B. Salit 206-667-1317 rsalit@fredhutch.org Principal Investigator: Rachel B. Salit 收起 <<
NCT02087059	Primary Myelofibrosis (MF)	Phase 3	Completed	-	Japan ... 展开 >> Novartis Investigative Site Nagoya-city, Aichi, Japan, 467-8602 Novartis Investigative Site Matsuyama, Ehime, Japan, 790-8524 Novartis Investigative Site Toon-city, Ehime, Japan, 791-0295 Novartis Investigative Site Fukuoka-city, Fukuoka, Japan, 812-8582 Novartis Investigative Site Kurume-city, Fukuoka, Japan, 830-0011 Novartis Investigative Site Maebashi-city, Gunma, Japan, 371-8511 Novartis Investigative Site Sapporo-city, Hokkaido, Japan, 060-8543 Novartis Investigative Site Sapporo-city, Hokkaido, Japan, 060-8648 Novartis Investigative Site Kobe-city, Hyogo, Japan, 650-0017 Novartis Investigative Site Kobe-city, Hyogo, Japan, 650-0047 Novartis Investigative Site Kumamoto City, Kumamoto, Japan, 860-8556 Novartis Investigative Site Kyoto-city, Kyoto, Japan, 606-8507 Novartis Investigative Site Tsu-city, Mie, Japan, 514-8507 Novartis Investigative Site Sendai-city, Miyagi, Japan, 980-8574 Novartis Investigative Site Miyazaki-city, Miyazaki, Japan, 889-1692 Novartis Investigative Site Okayama-city, Okayama, Japan, 700-8558 Novartis Investigative Site Hirakata-city, Osaka, Japan, 573-1191 Novartis Investigative Site OsakaSayama, Osaka, Japan, 589-8511 Novartis Investigative Site Suita-city, Osaka, Japan, 565-0871 Novartis Investigative Site Shimotsuke-city, Tochigi, Japan, 329-0498 Novartis Investigative Site Bunkyo-ku, Tokyo, Japan, 113-8431 Novartis Investigative Site Bunkyo-ku, Tokyo, Japan, 113-8519 Novartis Investigative Site Bunkyo-ku, Tokyo, Japan, 113-8603 Novartis Investigative Site Bunkyo-ku, Tokyo, Japan, 113-8677 Novartis Investigative Site Shinjuku-ku, Tokyo, Japan, 160-0023 Novartis Investigative Site Shinjuku-ku, Tokyo, Japan, 162-8666 Novartis Investigative Site Chuo-city, Yamanashi, Japan, 409-3898 Novartis Investigative Site Akita, Japan, 010-8543 Novartis Investigative Site Gifu, Japan, 501-1194 收起 <<
NCT00639002	-		Completed	-	-
NCT02087059	-		Completed	-	-
NCT02596347	-		Unknown	-	United States, Colorado ... 展开 >> National Jewish Health Recruiting Denver, Colorado, United States, 80206 Contact: Gina M Atnes, BA 303-398-1679 mondellog@njhealth.org Principal Investigator: Li Li, MD 收起 <<
NCT01186744	-		Completed	-	-
NCT02197455	Alopecia Areata (AA) ... 展开 >> Alopecia Totalis (AT) Alopecia Universalis (AU) 收起 <<	Phase 2	Completed	-	United States, Connecticut ... 展开 >> Yale University New Haven, Connecticut, United States 收起 <<
NCT02197455	-		Completed	-	-
NCT03440892	-		Recruiting	January 2020	Sweden ... 展开 >> Dept of Rheumatology and Inflammation research Recruiting Gothenburg, Sweden Contact: Sofia T Silfverswärd sofia.silfversward@rheuma.gu.se 收起 <<
NCT03660241	Hepatic Impairment	Phase 1	Recruiting	December 6, 2019	United States, Florida ... 展开 >> Orlando Clinical Research Center Recruiting Orlando, Florida, United States, 32809 Belgium Brussels Clinical Research Unit Recruiting Brussels, Be-bru, Belgium, B-1070 收起 <<
NCT00483756	Kidney Transplantation	Phase 2	Completed	-	-
NCT03635112	Crohn's Disease	Phase 2	Recruiting	September 2020	United States, Florida ... 展开 >> Theravance Biopharma Investigational Site Recruiting Aventura, Florida, United States, 33180 Theravance Biopharma Investigational Site Recruiting Clearwater, Florida, United States, 33765 Theravance Biopharma Investigational Site Recruiting Hialeah, Florida, United States, 33013 Theravance Biopharma Investigational Site Recruiting Largo, Florida, United States, 33777 Theravance Biopharma Investigational Site Recruiting Miami, Florida, United States, 33135 Theravance Biopharma Investigational Site Recruiting New Port Richey, Florida, United States, 34653 United States, Massachusetts Theravance Biopharma Investigational Site Recruiting Brockton, Massachusetts, United States, 02302 United States, Michigan Theravance Biopharma Investigational Site Recruiting Wyoming, Michigan, United States, 49519 United States, North Carolina PMG Research of Salisbury Recruiting Salisbury, North Carolina, United States, 28144 United States, Pennsylvania Theravance Biopharma Investigational Site Recruiting Pittsburgh, Pennsylvania, United States, 15213 United States, Texas Theravance Biopharma Investigational Site Recruiting Houston, Texas, United States, 77058 Theravance Biopharma Investigational Site Recruiting San Antonio, Texas, United States, 78215 Theravance Biopharma Investigational Site Recruiting Spring, Texas, United States, 77386 United States, Virginia Theravance Biopharma Investigational Site Recruiting Lansdowne Town Center, Virginia, United States, 20176 收起 <<
NCT03755297	Rheumatoid Arthritis	Not Applicable	Not yet recruiting	June 2020	-
NCT03745651	Atopic Dermatitis	Phase 3	Recruiting	September 2020	United States, Florida ... 展开 >> San Marcus Research Clinic Inc Recruiting Miami, Florida, United States, 33015 Well Pharma Medical Research Corporation Not yet recruiting Miami, Florida, United States, 33143 Forward Clinical Trials Inc Not yet recruiting Tampa, Florida, United States, 33624 United States, Georgia Clinical Research Atlanta Not yet recruiting Stockbridge, Georgia, United States, 30281 United States, Kentucky Derm Research LLC Not yet recruiting Louisville, Kentucky, United States, 40217 Dermatology Specialists PSC Not yet recruiting Louisville, Kentucky, United States, 40241 United States, New Hampshire ActivMed Practices & Research Inc Not yet recruiting Portsmouth, New Hampshire, United States, 03801 United States, New Jersey Hassman Research Institute Not yet recruiting Berlin, New Jersey, United States, 08009 United States, Ohio Synexus Clinical Research US, Inc. - Cincinnati Not yet recruiting Cincinnati, Ohio, United States, 45236 United States, Pennsylvania Paddington Testing Company Inc Not yet recruiting Philadelphia, Pennsylvania, United States, 19103 United States, South Carolina Synexus Clinical Research US, Inc. - Anderson Not yet recruiting Anderson, South Carolina, United States, 29621 United States, Texas Clinical Trials of Texas Incorporated Not yet recruiting San Antonio, Texas, United States, 78229 Center for Clinical Studies Not yet recruiting Webster, Texas, United States, 77598 United States, Virginia Clinical Research Partners LLC Not yet recruiting Henrico, Virginia, United States, 23233 United States, Washington Dermatology Specialists of Spokane Not yet recruiting Spokane, Washington, United States, 99204 收起 <<
NCT03758443	Ulcerative Colitis (UC)	Phase 2 Phase 3	Not yet recruiting	July 2025	United States, Florida ... 展开 >> Theravance Biopharma Investigational Site Not yet recruiting Largo, Florida, United States, 33777 收起 <<
NCT01236352	Cancer	Phase 1 Phase 2	Completed	-	United States, Minnesota ... 展开 >> Mayo Clinic Rochester, Minnesota, United States, 55905 United States, New York The Mount Sinai School Of Medicine New York, New York, United States, 10029 United States, Texas The University Of Texas Md Anderson Cancer Center Houston, Texas, United States, 77030 Australia, Victoria Local Institution East Melbourne, Victoria, Australia, 3002 Local Institution Melbourne, Victoria, Australia, 3050 收起 <<
NCT00483756	-		Completed	-	-
NCT03314402	Healthy Volunteers	Phase 1	Recruiting	October 2018	China, Jilin ... 展开 >> First Hospital of Jilin University Recruiting Chang Chun, Jilin, China Contact: Yanhua Ding, MD +86-18186879768 dingyanhua2003@126.com 收起 <<
NCT03670069	Metastatic Leiomyosarcoma ... 展开 >> Metastatic Synovial Sarcoma Metastatic Undifferentiated Pleomorphic Sarcoma Round Cell Liposarcoma 收起 <<	Phase 1	Not yet recruiting	June 1, 2022	United States, Washington ... 展开 >> Fred Hutch/University of Washington Cancer Consortium Not yet recruiting Seattle, Washington, United States, 98109 Contact: Seth Pollack 收起 <<
NCT03662516	Healthy Females	Phase 1	Recruiting	December 2018	United States, Connecticut ... 展开 >> Pfizer New Haven Clinical Research Unit Recruiting New Haven, Connecticut, United States, 06511 收起 <<
NCT00556257	Kidney Transplantation	Phase 2	Withdrawn	-	-
NCT01914484	Chronic Phase Chronic Myeloid ... 展开 >>Leukemia Accelerated Phase Chronic Myeloid Leukemia Blastic Phase Chronic Myeloid Leukemia Philadelphia Positive Acute Lymphoblastic Leukemia Resistant to Tyrosine Kinase Inhibitor Therapy 收起 <<	Phase 1 Phase 2	Unknown	July 2016	Canada, Ontario ... 展开 >> Princess Margaret Hospital / University Health Network Recruiting Toronto, Ontario, Canada, M5G 2M9 Contact: Sima Bogomilsky, RN BScN CON(C) 416-946-4646 sima.bogomilsky@uhn.on.ca Contact: Sonal Malhotra, M.Sc., Ph.D,CCRP 416-946-4501 ext 3449 sonal.malhotra@uhn.ca Principal Investigator: Dennis Kim, MD/PhD Sub-Investigator: Jeffrey H Lipton, MD/PhD 收起 <<
NCT03112603	Graft-versus-host Disease (GVH... 展开 >>D) 收起 <<	Phase 3	Recruiting	January 2022	-
NCT02370706	Myelofibrosis	Phase 1	Active, not recruiting	December 31, 2018	Australia, Melbourne ... 展开 >> Novartis Investigative Site VIC, Melbourne, Australia, 3004 Canada, Ontario Novartis Investigative Site Toronto, Ontario, Canada, M5G 2M9 France Novartis Investigative Site Villejuif Cedex, France, 94805 Germany Novartis Investigative Site Mainz, Germany, 55131 Novartis Investigative Site Ulm, Germany, 89081 Italy Novartis Investigative Site Firenze, FI, Italy, 50134 Netherlands Novartis Investigative Site Rotterdam, Netherlands, 3015 CE Singapore Novartis Investigative Site Singapore, Singapore, 119228 United Kingdom Novartis Investigative Site London, United Kingdom, SE1 9RT 收起 <<
NCT02997280	Graft Vs Host Disease	Phase 2	Recruiting	June 2019	Russian Federation ... 展开 >> First Pavlov State Medical University of St. Petersburg Recruiting Saint-Petersburg, Russian Federation, 197089 Contact: Ivan S. Moiseev, PhD +79217961951 moisiv@mail.ru Contact: Boris V. Afanasyev, Prof +78122334551 coordinatorbmt@gmail.com 收起 <<
NCT02226172	-		Terminated	-	-
NCT01835197	Healthy	Phase 1	Completed	-	United States, Connecticut ... 展开 >> Pfizer Investigational Site New Haven, Connecticut, United States, 06511 收起 <<
NCT01773187	Primary Myelofibrosis ... 展开 >> Post-polycythemia Vera Myelofibrosis Post-essential Thrombocythemia Myelofibrosis 收起 <<	Phase 3	Terminated	-	-
NCT01712659	T Cell Leukemia, Adult ... 展开 >> Leukemia, Adult T-Cell T Cell Leukemia, HTLV I Associated 收起 <<	Phase 2	Recruiting	November 1, 2021	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office 888-624-1937 收起 <<
NCT02226172	Primary Myelofibrosis; Post-po... 展开 >>lycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis 收起 <<	Phase 2	Terminated	-	United States, Arizona ... 展开 >> Mayo Clinic Building - Phoenix Phoenix, Arizona, United States, 85054 Mayo Clinic Hospital Phoenix, Arizona, United States, 85054 Mayo Clinic Scottsdale, Arizona, United States, 85259 United States, California UC San Diego Moores Cancer Center - Investigational Drug Services La Jolla, California, United States, 92037-0845 UCSD Medical Center Clinical Laboratory - La Jolla La Jolla, California, United States, 92037 University of California San Diego (UCSD) Moores Cancer Center La Jolla, California, United States, 92093-0698 UC San Diego Medical Center- Hillcrest San Diego, California, United States, 92103 United States, Michigan University of Michigan Ann Arbor, Michigan, United States, 48109 United States, New York Weill Cornell Medical College - New York-Presbyterian Hospital New York, New York, United States, 10021 Herbert Irving Comprehensive Cancer Center-Columbia University Medical Center New York, New York, United States, 10032 Weill Cornell Medical College-New York Presbyterian Hospital New York, New York, United States, 10065 United States, Ohio Cleveland Clinic - Taussig Cancer Institute Cleveland, Ohio, United States, 44195 United States, Utah Huntsman Cancer Institute-University of Utah Salt Lake City, Utah, United States, 84112 University of Utah, Huntsman Cancer Hospital Salt Lake City, Utah, United States, 84112 United States, Wisconsin Froedtert Hospital and Medical College of Wisconsin Milwaukee, Wisconsin, United States, 53226-3522 Japan Kobe University Hospital Kobe, Hyogo, Japan, 6500017 Osaka University Hopsital Suita-Shi, Osaka, Japan, 565-0871 Juntendo University Hospital Bunkyo-ku, Tokyo, Japan, 113-8431 Tokyo Medical University Hospital Tokyo, Japan, 160-0023 收起 <<
NCT03584516	Chronic Graft-versus-host Dise... 展开 >>ase 收起 <<	Phase 3	Not yet recruiting	October 17, 2023	-
NCT02953678	Graft-versus-host Disease (GVH... 展开 >>D) 收起 <<	Phase 2	Active, not recruiting	June 2020	-
NCT03320642	Hematologic Malignancies	Phase 1	Recruiting	January 2021	-
NCT00853385	Rheumatoid Arthritis	Phase 3	Completed	-	-
NCT01751425	Chronic Myelogenous Leukemia, ... 展开 >>BCR-ABL1 Positive Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission Minimal Residual Disease Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia 收起 <<	Phase 1 Phase 2	Recruiting	July 31, 2020	United States, Texas ... 展开 >> M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Jorge E. Cortes 713-794-5783 Principal Investigator: Jorge E. Cortes 收起 <<
NCT02164500	Recurrent Classical Hodgkin Ly... 展开 >>mphoma 收起 <<	Phase 2	Recruiting	December 2018	Germany ... 展开 >> 1st Dept. of Medicine, Cologne University Hospital Recruiting Cologne, Germany, 50924 Contact: Michael Fuchs ghsg@uk-koeln.de 收起 <<
NCT00658359	Kidney Transplantation	Phase 2	Completed	-	-
NCT00853385	-		Completed	-	-
NCT01904123	Metastatic Malignant Neoplasm ... 展开 >>in the Brain Metastatic Melanoma Recurrent Brain Neoplasm Recurrent Glioblastoma Recurrent Malignant Glioma 收起 <<	Phase 1	Recruiting	July 31, 2021	United States, Texas ... 展开 >> M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Amy B. Heimberger 713-563-8717 Principal Investigator: Amy B. Heimberger 收起 <<
NCT03647670	Phase 1	Phase 1	Completed	-	Belgium ... 展开 >> Pfizer Clinical Research Unit Brussels, Belgium, B-1070 收起 <<
NCT02531191	Healthy Volunteers	Phase 1	Completed	-	Japan ... 展开 >> Tokyo, Japan 收起 <<
NCT02759731	Chronic Graft vs Host Disease ... 展开 >> Chronic Graft-Versus-Host Disease 收起 <<	Phase 1 Phase 2	Recruiting	June 1, 2020	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office 888-624-1937 收起 <<
NCT01877005	Hodgkin's Lymphoma	Phase 2	Completed	-	Belgium ... 展开 >> UCL Louvain St Luc Brussels, Belgium, 10200 Université Catholique de Louvain Mont Godinne Yvoir, Belgium, 5530 France Chu Cote de Nacre Caen, France, 14000 Hopital Henri Mondor Creteil, France, 94010 Chu Dijon Dijon, France, 21000 Chru de Lille Lille, France, 59037 Centre Leon Berard Lyon, France, 69373 Centre Hospitalier Lyon Sud Lyon, France, 69495 CHU de Nantes, Hotel Dieu Nantes, France, 44093 Centre Henri Becquerel Rouen, France, 76038 收起 <<
NCT01730248	Myelofibrosis	Phase 1	Completed	-	Australia, Queensland ... 展开 >> Novartis Investigative Site Herston, Queensland, Australia, 4029 Australia, Victoria Novartis Investigative Site Melbourne, Victoria, Australia, 3000 Austria Novartis Investigative Site Vienna, Austria, A-1090 France Novartis Investigative Site Paris, France, 75010 Germany Novartis Investigative Site Berlin, Germany, 13353 Novartis Investigative Site Rostock, Germany, 18057 Israel Novartis Investigative Site Jerusalem, Israel, 91120 Novartis Investigative Site Ramat Gan, Israel, 5265601 Italy Novartis Investigative Site Firenze, FI, Italy, 50134 Novartis Investigative Site Varese, VA, Italy, 21100 Singapore Novartis Investigative Site Singapore, Singapore, 169608 Spain Novartis Investigative Site Madrid, Spain, 28041 United Kingdom Novartis Investigative Site Edgbaston, Birmingham, United Kingdom, B15 2WB Novartis Investigative Site London, United Kingdom, NW1 2BU Novartis Investigative Site London, United Kingdom, SE1 9RT 收起 <<
NCT03677648	Crohn's Disease	Phase 2	Not yet recruiting	August 31, 2020	-
NCT03742973	Primary Biliary Cholangitis	Phase 2	Not yet recruiting	October 15, 2020	United States, California ... 展开 >> Southern California GI and Liver Centers (SCLC) Not yet recruiting Coronado, California, United States, 92118 Contact 619-522-0399 Principal Investigator: Tarek Hassanein Cedars-Sinai Comprehensive Transplant Center Not yet recruiting Los Angeles, California, United States, 90048 Contact 310-423-6000 Principal Investigator: Vinay Sundaram UC Davis Transplant Research Not yet recruiting Sacramento, California, United States, 95816 Contact 916-734-0779 Principal Investigator: Christopher Bowlus United States, Colorado University of Colorado School of Medicine Not yet recruiting Aurora, Colorado, United States, 80045 Contact 728-848-2292 Principal Investigator: Lisa Forman United States, Florida Florida Digestive Health Specialists Not yet recruiting Lakewood Ranch, Florida, United States, 34211 Contact 941-727-7772 Principal Investigator: Guy W Neff Schiff Center for Liver Diseases/University of Miami Not yet recruiting Miami, Florida, United States, 33136 Contact 305-243-4615 Principal Investigator: Cynthia Levy United States, Louisiana Tulane University School of Medicine Not yet recruiting New Orleans, Louisiana, United States, 70112 Contact 504-988-5344 Principal Investigator: Fredric Regenstein United States, Maryland The Institute for Digestive Health and Liver Disease at Mercy Not yet recruiting Baltimore, Maryland, United States, 21202 Contact 410-332-9356 Principal Investigator: Paul Thuluvath United States, Michigan Henry Ford Hospital Not yet recruiting Detroit, Michigan, United States, 48202 Contact 313-916-9465 Principal Investigator: Stuart Gordon United States, Minnesota Mayo Clinic Not yet recruiting Rochester, Minnesota, United States, 55905 Contact 507-284-3917 Principal Investigator: John Eaton United States, Missouri St Louis University School of Medicine Not yet recruiting Saint Louis, Missouri, United States, 63104 Contact 314-577-8764 Principal Investigator: Bruce Bacon United States, Ohio UH Cleveland Medical Center Not yet recruiting Cleveland, Ohio, United States, 44106 Contact 216-844-5387 Principal Investigator: Anthony Post United States, Texas Baylor College of Medicine Not yet recruiting Houston, Texas, United States, 77030 Contact 713-798-1966 Principal Investigator: John Vierling Italy Azienda Ospedaliera San Gerardo Not yet recruiting Monza, Milano, Italy, 20052 Contact 390392333673 Principal Investigator: Pietro Invernizzi Istituto Clinico Humanitas Not yet recruiting Rozzano, Milano, Italy, 20089 Contact 390282244556 Principal Investigator: Ana Lleo De Nalda Azienda Ospedaliera Umberto I Not yet recruiting Ancona, Italy, 60124 Contact 390715963377 Principal Investigator: Marco Marzioni Puerto Rico Klinical Investigations Group, LLC Not yet recruiting San Juan, Puerto Rico, 00909 Contact 7879197865 Principal Investigator: Federico Rodriguez University of Puerto Rico, Medical Sciences Campus Not yet recruiting San Juan, Puerto Rico, 00936 Contact 7877540101 Principal Investigator: Esther A. Torres 收起 <<
NCT01745055	Rheumatoid Arthritis	Phase 1	Completed	-	United States, Florida ... 展开 >> Pfizer Investigational Site Daytona Beach, Florida, United States, 32114 Pfizer Investigational Site Fort Lauderdale, Florida, United States, 33301 Pfizer Investigational Site Miramar, Florida, United States, 33025 United States, Texas Pfizer Investigational Site Dallas, Texas, United States, 75247 收起 <<
NCT01745055	-		Completed	-	-
NCT03627403	Primary Myelofibrosis ... 展开 >> Post-essential Thrombocythemia Myelofibrosis Post-polycythemia Vera Myelofibrosis 收起 <<	Phase 2	Not yet recruiting	November 2023	-
NCT03675477	Ulcerative Colitis	Phase 2	Not yet recruiting	July 30, 2020	-
NCT03745638	Atopic Dermatitis	Phase 3	Recruiting	September 2020	-
NCT02559492	Solid Tumors	Phase 1	Active, not recruiting	June 2019	United States, California ... 展开 >> Duarte, California, United States United States, Colorado Denver, Colorado, United States United States, Connecticut New Haven, Connecticut, United States United States, Florida Tampa, Florida, United States United States, Illinois Chicago, Illinois, United States United States, Minnesota Rochester, Minnesota, United States United States, North Carolina Huntersville, North Carolina, United States United States, Tennessee Nashville, Tennessee, United States United States, Texas Dallas, Texas, United States Houston, Texas, United States United States, Utah Salt Lake City, Utah, United States 收起 <<
NCT02158858	Myelofibrosis ... 展开 >> Leukemia, Myelocytic, Acute Myelodysplastic/Myeloproliferative Neoplasm Myelodysplastic Syndrome (MDS) 收起 <<	Phase 1 Phase 2	Recruiting	March 2020	United States, California ... 展开 >> UCLA Medical Center Recruiting Los Angeles, California, United States, 90095 Contact: Farzam Hariri FHariri@mednet.ucla.edu Principal Investigator: Gary Schiller, MD United States, Indiana Horizon Oncology Center Recruiting Lafayette, Indiana, United States, 47905 Contact: Wael Harb, MD 765-446-5111 info@horizonbioadvance.com Principal Investigator: Wael Harb, MD United States, Massachusetts Massachusetts General Hospital Active, not recruiting Boston, Massachusetts, United States, 02114 United States, New York Icahn School of Medicine at Mount Sinai Recruiting New York, New York, United States, 10029 Contact: Frank Fabris 212-241-8999 frank.fabris@mssm.edu Principal Investigator: Marina Kremyanskya, MD PhD Columbia University Medical Centre Recruiting New York, New York, United States, 10032 Contact: Mackenzie Snead mbs2173@cumc.columbia.edu Principal Investigator: Mark Heaney Memorial Sloan-Kettering Cancer Center Active, not recruiting New York, New York, United States, 10065 United States, Ohio Gabrail Cancer Center Recruiting Canton, Ohio, United States, 44718 Contact: Carrie Smith, RN CSmith@GabrailCancerCenter.com Principal Investigator: Nashat Gabrail, MD United States, Pennsylvania University of Pennsylvania - Perelman Center for Advanced Medicine Active, not recruiting Philadelphia, Pennsylvania, United States, 19104 United States, Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Kurt Schroeder, RN 713-563-2622 kdschroe@mdanderson.org Principal Investigator: Prithviraj Bose, MD Canada, Alberta University of Alberta Hospital Recruiting Edmonton, Alberta, Canada, T6G 2G3 Contact: Lori Rackel 780-407-1811 lori.rackel@albertahealthservices.ca Principal Investigator: Elena Liew, MD Canada, British Columbia St. Paul's Hospital Recruiting Vancouver, British Columbia, Canada, V6Z 2A5 Contact: Rachel Despotovic 604-875-5296 rachel.despotovic@vch.ca Principal Investigator: Lynda Foltz, MD Canada, Ontario Juravinski Cancer Centre Recruiting Hamilton, Ontario, Canada, L8V 5C2 Contact: Elisa Shore elisa.shore@jcc.hhsc.ca Principal Investigator: Brian Leber Princess Margaret Cancer Centre Recruiting Toronto, Ontario, Canada, M5G 2M9 Contact: Sabina Naqvi 416-581-8619 sabina.naqvi@uhn.ca Principal Investigator: Vikas Gupta, MD 收起 <<
NCT00658359	-		Completed	-	-
NCT02646748	Colorectal Cancer (CRC) ... 展开 >> Endometrial Cancer Melanoma Head and Neck Cancer Lung Cancer MMR-deficient Tumors Breast Cancer Pancreatic Cancer Renal Cell Carcinoma (RCC) Solid Tumors UC (Urothelial Cancer) 收起 <<	Phase 1	Recruiting	August 2019	United States, California ... 展开 >> University of California San Francisco Helen Diller Family Comprehensive Cancer Center Recruiting San Francisco, California, United States, 94143 Contact: Study Coordinator Claire Hooker 415-885-3728 Claire.Hooker@ucsf.edu John Wayne Cancer Institute at Providence Saint John's Health Center Recruiting Santa Monica, California, United States, 90404 Contact: Study Coordinator Aleksandra Dubinchick 310-582-7249 Aleksandra.Dubinchik@providence.org United States, District of Columbia Georgetown University Medical Center Lombardi CCC Recruiting Washington, District of Columbia, United States, 20007 Contact: Study Coordinator Jennifer Montcalm, RN 202-687-8974 jem257@georgetown.edu United States, Florida Hematology-Oncology Associates of Treasure Coast Recruiting Port Saint Lucie, Florida, United States, 37952 Contact: Study Coordinator Heather Austin 772-408-5158 haustin@hemoncfl.com United States, Maryland The Center for Cancer and Blood Disorders (RCCA MD LLC-Maryland Vidision) Recruiting Bethesda, Maryland, United States, 20817 Contact: Study Coordinator Jennifer Cipriano, CRC 240-482-0556 jcipriano@ccbdmd.com United States, Massachusetts Beth Israel Medical Deaconess Medical Center Recruiting Boston, Massachusetts, United States, 02215 Contact: Study Coordinator Steven Buccholz 617-632-9280 sbucchol@bidmc.harvard.edu Dana Farber Cancer institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Study Coordinator Amanda Stroiney 617-632-3289 Amanda_Stroiney@dfci.harvard.edu United States, Michigan Karmanos Cancer Center Recruiting Detroit, Michigan, United States, 48201 Contact: Study Coordinator 313-576-9749 schneidk@karmanos.org Henry Ford Hospital System Recruiting Detroit, Michigan, United States, 48202 Contact: Study Coordinator Kayliegh McEachren 313-916-9459 kmceach2@hfhs.org United States, Missouri St. Luke's Hospital of Kansas City Recruiting Kansas City, Missouri, United States, 64111 Contact: Study Coordinator 816-932-2677 mlising@saint-lukes.org United States, New York NYU Laura & Isaac Perlmutter Cancer Center at NYU Langone Recruiting New York, New York, United States, 10016 Contact: Study Coordinator Cindy Parasram 646-754-7146 Cindy.Parasram@nyumc.org United States, North Carolina Duke Cancer Institute Recruiting Durham, North Carolina, United States, 27710 Contact: Study Coordinator Shawna Savage 919-668-1462 shawna.savage@duke.edu United States, Pennsylvania UPMC CancerCenters, Hilman Cancer Center Recruiting Pittsburgh, Pennsylvania, United States, 15232 Contact: Study Coordinator Andrea Chavlovich 412-623-7029 chavlovicha@upmc.edu United States, Texas HOPE Cancer Center of East Texas Recruiting Tyler, Texas, United States, 75701 Contact: Study Coordinator Briana Schamber, RN 903-595-7045 bschamber@HopeCancerTexas.com United States, Utah Utah Cancer Specialists Recruiting Salt Lake City, Utah, United States, 84106 Contact: Study Coordinator Casey Larsen 801-270-2238 ext 224 clarsen@utahcancer.com 收起 <<
NCT03662126	Primary Myelofibrosis (PMF) ... 展开 >> Post-Polycythemia Vera MF (Post-PV-MF) Post-Essential Thrombocythemia MF (Post-ET-MF) 收起 <<	Phase 2	Recruiting	February 28, 2023	United States, California ... 展开 >> Innovative Clinical Research Institute Recruiting Whittier, California, United States, 90603 Contact: Kirsten Bettino 562-693-4477 kbettino@airesearch.us United States, Florida University Cancer Institute Recruiting Boynton Beach, Florida, United States, 33426 Contact: Paula Ortiz 561-737-6556 portiz@universitycancerinstitute.com United States, Minnesota Health Partners Institute Recruiting Saint Paul, Minnesota, United States, 55101 Contact: Jennifer Collier 651-254-3391 jennifer.collier@parknicollet.com United States, Missouri Washington University School of Medicine Recruiting Saint Louis, Missouri, United States, 63110 Contact: Karyn Gordon 314-362-9236 kdgordon@wustl.edu United States, New Jersey Summit Medical Group Recruiting Florham Park, New Jersey, United States, 07932 United States, Ohio Gabrail Cancer Center Recruiting Canton, Ohio, United States, 44718 Contact: Carrie Smith 330-492-3345 ext 208 csmith@gabrailcancercenter.com 收起 <<
NCT01969838	Primary Myelofibrosis ... 展开 >> Post-Polycythemia Vera Myelofibrosis Post-Essential Thrombocythemia Myelofibrosis 收起 <<	Phase 3	Active, not recruiting	March 2019	-
NCT00860496	Healthy Volunteers	Phase 1	Completed	-	Singapore ... 展开 >> Pfizer Investigational Site Singapore, Singapore, 188770 收起 <<
NCT02535689	Systemic Lupus Erythematosus	Phase 1	Completed	-	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT01317875	Myelofibrosis	Phase 1	Active, not recruiting	September 2020	United States, Florida ... 展开 >> Winter Park, Florida, United States, 32789 United States, Maryland Baltimore, Maryland, United States, 21229 United States, Texas Houston, Texas, United States, 77030 Austria Vienna, Austria China, Jiangsu Nanjing, Jiangsu, China China, Sichuan Chengdu, Sichuan, China China, Zhejiang Hangzhou, Zhejiang, China China Beijing, China France Angers, France Paris, France Pierre-Benite, France Germany Leipzig, Germany Italy Firenze, Italy Milano, Italy Terni, Italy Netherlands Rotterdam, Netherlands United Kingdom Belfast, United Kingdom London, United Kingdom 收起 <<
NCT03450330	Nonsmall Cell Lung Cancer	Phase 1 Phase 2	Recruiting	July 2022	Australia, Victoria ... 展开 >> Austin Hospital Recruiting Heidelberg, Victoria, Australia, 3084 Contact: Sarah Healy Principal Investigator: Tom John Australia Northern Cancer Institute St Leonards Active, not recruiting Sydney, Australia, 2066 收起 <<
NCT02723994	Leukemia	Phase 2	Recruiting	May 2024	-
NCT03766399	Asthma	Phase 1	Recruiting	December 5, 2019	United Kingdom ... 展开 >> Research Site Recruiting Harrow, United Kingdom, HA1 3UJ Research Site Not yet recruiting Manchester, United Kingdom, M23 9GP 收起 <<
NCT02265510	Solid Tumors ... 展开 >>Advanced Malignancies Metastatic Cancer 收起 <<	Phase 1 Phase 2	Active, not recruiting	June 2019	United States, Alabama ... 展开 >> Birmingham, Alabama, United States United States, California West Hollywood, California, United States United States, Connecticut New Haven, Connecticut, United States United States, Georgia Atlanta, Georgia, United States United States, Indiana Indianapolis, Indiana, United States United States, North Carolina Greenville, North Carolina, United States United States, Oregon Portland, Oregon, United States United States, Tennessee Nashville, Tennessee, United States United States, Texas Dallas, Texas, United States 收起 <<
NCT00263328	-		Completed	-	-
NCT00263328	Kidney Transplantation	Phase 2	Completed	-	United States, California ... 展开 >> Multi Organ Transplant Center Los Angeles, California, United States, 90057 St. Vincent Medical Center Los Angeles, California, United States, 90057 Transplant Research Institute Los Angeles, California, United States, 90057 Stanford School of Medicine Palo Alto, California, United States, 94304 Balboa Institute of Transplantation San Diego, California, United States, 92123 California Institute of Renal Research San Diego, California, United States, 92123 Sharp Memorial Hospital San Diego, California, United States, 92123 California Pacific Medical Center San Francisco, California, United States, 94115 University of California, San Francisco, Kidney Transplant Unit San Francisco, California, United States, 94143 Stanford University Medical Center Stanford, California, United States, 94305 United States, Colorado University of Colorado Health Sciences Center Renal Clinical Trials Office Aurora, Colorado, United States, 80045 University of Colorado Health Sciences Center Aurora, Colorado, United States, 80045 United States, Illinois Northwestern Memorial Hospital Chicago, Illinois, United States, 60611 Northwestern University-Feinberg School of Medicine, Division of Organ Transplantation Chicago, Illinois, United States, 60611 United States, Missouri Washington University School of Medicine St. Louis, Missouri, United States, 63110 United States, New York Jack J Dreyfus Clinic New York, New York, United States, 10021 Recanati/Miller Transplantation Institute New York, New York, United States, 10029 New York Presbyterian Hospital / Weill Cornell Medical Center New York, New York, United States, 10065 United States, Oregon Legacy Good Samaritan Hospital Portland, Oregon, United States, 97210 Legacy Transplant Services Portland, Oregon, United States, 97210 Northwest Renal Clinic Portland, Oregon, United States, 97210 United States, Texas Dallas Transplant Institute Dallas, Texas, United States, 75204 Annette C & Harold C Simmons Transplant Institute Dallas, Texas, United States, 75246 Baylor University Medical Center Dallas, Texas, United States, 75246 Baylor All Saints Medical Center Fort Worth, Texas, United States, 76104 United States, Wisconsin Froedtert Memorial Lutheran Hospital Milwaukee, Wisconsin, United States, 53226 Medical College of Wisconsin Milwaukee, Wisconsin, United States, 53226 收起 <<
NCT01929941	Solid Tumor H... 展开 >>odgkin's Lymphoma NHL (Non-Hodgkin Lymphoma) Pancreatic Cancer Breast Cancer UC (Ureter and Urethera) Advanced Cancer Metastatic Cancer 收起 <<	Phase 1	Terminated(Business decision.)	-	United States, Georgia ... 展开 >> Atlanta, Georgia, United States United States, Tennessee Nashville, Tennessee, United States United States, Texas Dallas, Texas, United States 收起 <<
NCT03755414	Acute Myelogenous Leukemia ... 展开 >> Acute Lymphocytic Leukemia Myelodysplastic Syndromes Non-Hodgkin Lymphoma Hodgkin Disease 收起 <<	Phase 1	Not yet recruiting	February 28, 2022	United States, Missouri ... 展开 >> Washington University School of Medicine Saint Louis, Missouri, United States, 63110 收起 <<

CAS号	2096999-92-5
分子式	C₂₇H₃₁FN₆O
分子量	474.57
SMILES Code	OC1=CC(CC)=C(C2=CC3=C(C=C2)C(C(N4)=NC5=C4CN(C6CCN(C)CC6)CC5)=NN3)C=C1F
MDL No.	N/A

JAK-IN-5 {[allProObj[0].p_purity_real_show]}

JAK-IN-5 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

JAK-IN-5 质控信息

JAK-IN-5 生物活性

JAK-IN-5 临床研究

JAK-IN-5 实验方案

JAK-IN-5 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

别名
运输	蓝冰

JAK-IN-5 {[allProObj[0].p_purity_real_show]}

JAK-IN-5 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

JAK-IN-5 质控信息

JAK-IN-5 生物活性

JAK-IN-5 临床研究

JAK-IN-5 实验方案

JAK-IN-5 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

JAK-IN-5 纯度/质量文件产品仅供科研